Rivia funding news – Zurich-based Rivia Secures €3 Million in Seed Funding

In addition to advancing product development to fully realise the promise of integrated trial data and solidify its position as the single data platform for biopharma clinical trials, the money will be utilised to create new teams in the engineering and client services departments.

With only 13% of treatments that enter clinical trials making it to market, Biotech is making this investment at a critical juncture, given the complexity of therapeutic development and intensifying competition challenges.

The goal of Rivia is to revolutionise the clinical trial process so that Biotechs can use its technologies to produce novel treatments with increased success. Rivia, which was founded by seasoned biopharma experts acquainted with the challenges facing the sector, specialises in developing software that is easy to use and meets the demands of biotech companies.

Read also - Raily funding news – Germany-based Raily Raises €1.5Million in Pre-Seed Funding

Through the resolution of problems like disjointed data and antiquated visualisation instruments, Rivia is transforming the process of conducting clinical trials. Thanks to the company's cutting-edge technology, biotechs can now analyse trial data more effectively, paving the way for faster and more successful therapy launches.

Erik Scalfaro, CEO and co-founder of Rivia said: “Our technology transcends data integration and changes how biotechs evaluate their therapies throughout their development lifecycle. Our founding expertise lies in consolidating information from clinical trial service providers and offering self-service analytics for medical and clinical operations. This year, we’re introducing AI-powered analytics and AI-enabled workflows to enhance data interactions. Our mission is to equip biotechs with tools to develop transformative, life-saving therapies and we’re thrilled by the promising signals we’re seeing.”

Rivia solves a major inefficiency in the market: the state-of-the-art in data collecting is not matched by system integration capabilities or easily navigable web apps that necessitate minimal customisation.

The shift to novel drug therapies, such as mRNA vaccines, recently approved gene-editing therapies2, and AI-discovered drugs3, highlights the urgent need to move away from antiquated, slow clinical trial procedures and towards a quick, tech-centric strategy that can handle the uncertainties surrounding these ground-breaking therapies4.

Andrea Zitna, Partner at Speedinvest said, “We at Speedinvest are beyond excited to work closely with Erik and Tiago and lead Rivia’s seed round. Rivia’s infrastructure and AI-powered platform fundamentally changes how biotech companies access and analyze their clinical trial data, glean insights and make real-time decisions. The feedback from their customers is phenomenal and we believe Rivia has the potential to become the gold standard in the industry,”.

Marta G. Zanchi, Founder & Managing Partner at Nina Capital said, “Rivia stands out for its unique approach to centralizing and visualizing multiple sources of clinical trial data in real-time, requiring minimal integration efforts and enabling proactive patient monitoring. We strongly believe Rivia’s two-pronged value proposition, focused on enhancing operational efficiency and reducing risks, is exactly what thousands of biotechs globally have been waiting for — and we are excited to see this European company deliver on it with such deep domain expertise, creativity, and ingenuity,”.

About Rivia

Rivia is an expert in data infrastructure and AI-driven analytics for biopharmaceutical clinical trials that are more successful. The majority of innovative treatments originate from biopharmas, yet because of antiquated technologies and fragmented data, they frequently experience inefficiencies and failures in clinical trials. Their platform provides an integrated, real-time view of data to enhance the way trials are conducted and potential therapies are evaluated.